[225Ac]Ac-PSMA I&T治疗mCRPC的1期剂量递增研究:安全性、耐受性与剂量学分析
该1期剂量递增研究纳入9例转移性去势抵抗性前列腺癌患者,接受2周期8–12 MBq [225Ac]Ac-PSMA I&T治疗。8例出现不良事件,口干最常见(89%);12 MBq队列出现2例剂量限制性毒性,推荐2期剂量为10 MBq。中位总生存15个月,基于平面图像、血尿分析和[68Ga]Ga-PSMA I&T PET/MRI估算红骨髓、肾脏、唾液腺和肿瘤的中位吸收剂量分别为0.21、1.59、1.43和11.22 Gy/MBq。
要点
- 推荐2期剂量为10 MBq,12 MBq队列出现2例剂量限制性毒性。
- 口干最常见(89%),贫血和乏力各占44%。
- 基于定量SPECT/CT的225Ac剂量学不可行,剂量学限于平面图像及血尿样本。
核心结论
- 该1期试验推荐[225Ac]Ac-PSMA I&T的2期剂量为10 MBq。
- 225Ac剂量学受限于全身平面图像及血尿样本,优化225Ac SPECT/CT成像可能使未来剂量学可行。
研究设计与样本
- 1期剂量递增研究,纳入9例mCRPC患者,接受2周期8–12 MBq [225Ac]Ac-PSMA I&T治疗。
- 治疗后密切监测不良事件,14周后按RECIST 1.1用[68Ga]Ga-PSMA I&T PET/MRI评估肿瘤反应。
- 剂量学基于注射后7天内13个时间点血样、24小时内尿样、10天内全身平面图像(含或不含SPECT/CT),用213Bi和221Fr子体计算时间-活性曲线。
主要发现
- 8/9例患者出现任何级别不良事件,口干最常见(89%),贫血和乏力各44%。
- 12 MBq队列出现2例剂量限制性毒性。
- 中位总生存为15个月(95% CI,0.0–32.5个月)。
- 基于平面图像、血尿分析和[68Ga]Ga-PSMA I&T PET/MRI,红骨髓、肾脏、唾液腺和肿瘤的中位吸收剂量分别为0.21、1.59、1.43和11.22 Gy/MBq。
- 4/9例(44%)患者PSA下降≥50%;RECIST 1.1评估部分缓解1例、稳定3例、进展3例、不可评估2例。
关键数值与推荐
- 推荐2期剂量为10 MBq [225Ac]Ac-PSMA I&T。
- PSA下降≥50%见于4/9例(44%)。
- RECIST 1.1评估:部分缓解1例、稳定3例、进展3例、不可评估2例。
- 中位总生存15个月(95% CI,0.0–32.5个月)。
临床怎么用
- 在mCRPC的[225Ac]Ac-PSMA I&T治疗中,2期推荐剂量为10 MBq。
- 治疗中需关注口干、贫血和乏力等不良事件。
- 225Ac剂量学目前可基于全身平面图像及血尿样本进行,定量SPECT/CT尚不可行。
局限性
- 样本量仅9例。
- 225Ac基于定量SPECT/CT的剂量学不可行,剂量学限于全身平面图像及血尿样本。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Radiopharmaceutical therapy with 225Ac-labeled prostate-specific membrane antigen (225Ac-PSMA) has shown promising results in patients with metastatic castration-resistant prostate cancer (mCRPC). To date, no phase 1 dose-escalation or comprehensive dosimetry study of [225Ac]Ac-PSMA I&T is available. Here, we present the results of the safety, tolerability, and dosimetry data of [225Ac]Ac-PSMA I&T in a phase 1 trial. Methods: Nine patients with mCRPC were treated with an intended 2 cycles of escalating activity of [225Ac]Ac-PSMA I&T, ranging from 8 to 12 MBq. After treatment with [225Ac]Ac-PSMA I&T, patients were closely monitored for adverse events. Tumor response was evaluated using [68Ga]Ga-PSMA I&T PET/MRI at 14 wk after therapy in accordance with RECIST version 1.1. For dosimetry, blood sampling was performed at 13 time points up to 7 d and urine sampling was conducted up to 24 h postinjection. Time-activity curves were calculated using the radionuclide daughters 213Bi and 221Fr. Whole-body planar images with or without SPECT/CT images were acquired up to 10 d postinjection. Results: Adverse events of any grade were observed in 8 of 9 patients. Xerostomia was most frequently (89%) reported, followed by anemia (44%) and malaise (44%). In the third cohort of patients who were treated with 12 MBq, 2 dose-limiting toxicities were observed, resulting in a recommended phase 2 dose of 10 MBq. The median overall survival was 15 mo (95% CI, 0.0-32.5 mo). The median absorbed doses for red marrow, kidneys, salivary glands, and tumors were 0.21, 1.59, 1.43, and 11.22 Gy/MBq, respectively, on the basis of planar images, blood and urine analysis, and [68Ga]Ga-PSMA I&T PET/MRI. Dosimetry based on quantitative SPECT/CT images was not feasible for 225Ac. A prostate-specific antigen response of 50% or greater was observed in 4 (44%) of 9 patients. Response was classified in accordance with RECIST 1.1, with partial response in 1 patient and stable and progressive disease in 3 patients each; 2 patients were not evaluable. Conclusion: The results of this phase 1 trial indicate a recommended phase 2 dose of 10 MBq of [225Ac]Ac-PSMA I&T. Dosimetry of [225Ac]Ac-PSMA I&T was limited to whole-body planar images and blood and urine samples. However, the optimization of 225Ac SPECT/CT imaging may enable future dosimetry of [225Ac]Ac-PSMA I&T.
引用
- Ling SW, Konijnenberg M, Segbers M, et al. Phase 1 Dose-Escalation Study of [225Ac]Ac-PSMA I&T in Patients with Metastatic Castration-Resistant Prostate Cancer: An Analysis of Safety, Tolerability, and Dosimetry. J Nucl Med. 2026. PMID: 42020144. doi:10.2967/jnumed.125.271880
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。